8-K
ZyVersa Therapeutics, Inc. (ZVSA)
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
February 8, 2022
Date of Report (Date of earliest event reported)
Larkspur Health Acquisition Corp.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001- 41184 | 86-2685744 |
|---|---|---|
| (State or other jurisdiction<br><br>of incorporation) | (Commission File Number) | (I.R.S. Employer<br><br>Identification No.) |
| 100 Somerset Corporate Blvd., 2^nd^ FloorBridgewater, New Jersey | 08807 | |
| --- | --- | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (609) 310-0722
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br>communications pursuant to Rule 425 under the Securities Act |
|---|---|
| ☐ | Soliciting<br>material pursuant to Rule 14a-12 under the Exchange Act |
| --- | --- |
| ☐ | Pre-commencement<br>communications pursuant to Rule 14d-2(b) under the Exchange Act |
| --- | --- |
| ☐ | Pre-commencement<br>communications pursuant to Rule 13e-4(c) under the Exchange Act |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Units, each consisting of one share of Class A Common Stock and three-fourths of one Redeemable Warrant | LSPRU | The Nasdaq Stock Market LLC |
| Class A Common Stock, par value $0.0001 per share | LSPR | The Nasdaq Stock Market LLC |
| Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share | LSPRW | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On February 8, 2022, Larkspur Health Acquisition Corp. (the “Company”) announced that the holders of the Company’s units (the “Units”) may elect to separately trade the Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock”), and warrants included in the Units commencing on February 10, 2022. Each Unit consists of one share of Class A Common Stock and three-fourths of one redeemable warrant to purchase one share of Class A Common Stock. Any Units not separated will continue to trade on Nasdaq Global Market under the symbol “LSPRU.” Any underlying Class A Common Stock and warrants that are separated will trade on the Nasdaq Global Market and trade under the symbols “LSPR” and “LSPRW,” respectively. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the holders’ Units into Class A Common Stock and warrants.
A copy of the press release issued by the Company announcing the separate trading of the securities underlying the Units is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit<br><br>No. | Description |
|---|---|
| 99.1 | Press release, dated February 8, 2022. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: February 8, 2022 | |
|---|---|
| LARKSPUR HEALTH ACQUISITION CORP. | |
| By: | /s/ Daniel J. O’Connor |
| Name: | Daniel J. O’Connor |
| Title: | Chief Executive Officer |
2
Exhibit 99.1
Larkspur Health Acquisition Corp. AnnouncesClass A Common Stock and Warrants to
Commence Trading Separately on February 10, 2022
New York, NY, Feb. 8, 2022 (BUSINESS WIRE) -- Larkspur Health Acquisition Corp. (NASDAQ: LSPRU, the “Company”) announced that the holders of the Company’s units may elect to separately trade the Class A Common Stock and redeemable warrants underlying such units commencing on February 10, 2022. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “LSPRU” and the Class A Common Stock and warrants that are separated will be listed on the Nasdaq Global Market and trade under the symbols “LSPR” and “LSPRW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of the Company’s units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate units into shares of Class A Common Stock and warrants.
About Larkspur Health Acquisition Corp.
Larkspur Health Acquisition Corp. is a blank check company whose business purpose is to effect a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on companies in the biotechnology sector and would benefit from access to public markets and the operational and strategic expertise of our management team and board of directors. The Company is sponsored by Larkspur Health LLC, a Delaware limited liability company, and led by Chairman and Chief Executive Officer, Daniel J. O’Connor and Director and Chief Financial Officer, David S. Briones.
Forward Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including the successful consummation of any future initial business combination, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.
Contacts:
Daniel J. O’Connor
+1-609-947-1476
David S. Briones
+1-908-370-5102
www.lsprhealth.com